Real-World Data Study Gives Look at Merck’s COVID Drug’s Performance After Middling Sales

Merck’s COVID-19 drug Lagrevio has suffered from middling sales since its emergency use authorization last December, with 755,000 of 2.5 million doses used. New real-world data (RWD) from the PANORAMIC study has shown positive results, with patients reporting that it cut average recovery times by 6 days. In addition, it cut the number of patients with detectable viral loads at day seven from 34 to 29.

According to Lei Lei Wu, “On the other hand, sales for Paxlovid have grown. Pfizer sold $1.5 billion worth of the drug in the first quarter, but that figure skyrocketed to $8.1 billion in the second quarter of the year. Separately, amid reports of Covid rebound following Paxlovid treatment, a tiny seven-patient study run by NIH scientists suggests that weak immune response is not the reason for rebound.”

To read more, click here.

(Source: Endpoints News, October 7^th, 2022)